

**EVAS: Empirical Validity and Safety**

Jake Galdo, Kelsey Holder, Courtney Tigges, Anthony Bolus, Sujith Ramachandran

Seguridad, Inc | Birmingham, AL

|  |  |
| --- | --- |
| **Objectives** | |
| To determine the empirical validity of quality measures implemented in the Choose My Pharmacy measurement system | |
| **Methods** | |
| Design | * A retrospective, chart review of quality improvement projects in three pharmacy companies: FMS, Inc, SEMO Rx Inc, and Towncrest Pharmacy |
| Study endpoints | * Measure performance on *Assessment of Weights in Pediatrics* and *Assessment of Renal Function in Older Adults* * Patient interventions based on findings from the measures |
| **Results** | |
| * Towncrest: 155 serum creatinine interventions   + 7 prescribers made interventions on patients to obtain serum creatinine once requested   + 2 medications required dosing adjustments * SEMORx: 155 prescriptions for pediatric antibiotics with interventions   + 70 prescriptions contained weight and diagnosis code from prescriber     - 42 prescriptions (60%) were dosed inappropriately and required intervention * FMS, Inc: 115 patients with pediatric interventions and 68 patients with serum creatinine interventions   + Of the pediatric patients:     - 103 prescriptions (89%) did NOT have a weight on file prior to intervention     - 54 prescriptions required weight-based dosing       * 2 prescriptions (4%) were dosed inappropriately (both antibiotics)   + Of the older adults:     - 0 patients had a weight on file initially     - 0 patients had a serum creatinine on file initially       * 103 prescriptions required dosing adjustment         + 13 (12.6%) were dosed inappropriately * Measure Performance:   + Q3 2021 Pediatric Measure     - FMS, Inc       * Ross Bridge: 0%       * FMS: 0%     - SEMO Rx:       * L&S: 77%   + Q3 2021 Serum Creatinine     - FMS, Inc       * Ross Bridge: 0%       * FMS: 0%     - SEMO Rx:       * L&S: 0%   + Q3 2022 Pediatric Measure     - FMS, Inc       * Ross Bridge: 19%       * FMS: 8.9%     - SEMO Rx:       * L&S: >90%   + Q3 2022 Serum Creatinine     - FMS, Inc       * Ross Bridge: 1.5%       * FMS: 1.1%     - SEMO Rx:       * L&S: 0.1% | |
| **Conclusion** | |
| This project showcases a few important aspects of community pharmacy practice. First, it is *feasible* for pharmacies to collect clinical data, like weight or serum creatinine. Secondly, it highlights the importance of this information during the dispensing process – both clinical laboratory values *when available* allowed pharmacies to make interventions to optimize medications and improve patient safety. Finally, this research shows the empirical validity of measuring a pharmacy’s performance on these measures. The data shows that improvement on the measures helps improve patient care, showing the measures are a valid assessment of pharmacy quality. | |